August 20, 2025
admin
Anondita Medicare IPO Key Dates
| Anchor Investor Subscription | |
| IPO opens on | 22 August 2025 |
| IPO Closes on | 26 August 2025 |
| Allotment on | 28 August 2025 |
| Credit of shares on | 29 August 2025 |
| Tentative Listing on | 1 Septmeber 2025 |
Anondita medicare Concise Review
The company operates in a niche healthcare category with strong export orientation and remarkable financial improvement. Given its robust topline growth, margin expansion, and association with reputed agencies, the IPO appears attractive from a medium to long-term perspective.
Final Subscription Tally
| Size Rs. Crore | ||||
| QIB | NII x | RII x | Total x | Applications |
| Subscription Review: |
||||
About Anondita Medicare
Anondita Medicare Limited, incorporated in March 2024, is engaged in the manufacturing of flavored male condoms under its flagship brand “COBRA.” The company has an installed production capacity of about 562 million condoms per year from its manufacturing facility located at Noida, Uttar Pradesh.
The company caters not only to the domestic market but also exports to international markets across Southeast Asia, Africa, and the Middle East. It works in close association with global health organizations, NGOs, and government agencies to promote family planning and public health initiatives.
Anondita Medicare has established a strong distribution network, ensuring timely supply through wholesalers, retailers, and e-commerce platforms. It also maintains long-standing ties with government health programs and institutions, contributing significantly to the supply of essential healthcare products.
As on July 31, 2025, the company employed 280 people.
Anondita Medicare IPO Details
|
Sector: Condom Manufacturing |
|
| IPO opens on | 22 August 2025 |
| IPO closes on | 26 August 2025 |
| Issue Type | Book Built Issue IPO |
| Issue Size | 47,93,000 Shares / Rs 69.50 Crore |
| * Fresh Issue | – |
| * Offer for Sale – | – |
| Market Maker Portion | 270,000 Shares |
| Net offer to Public | 45,23,000 Shares Rs. 65.58 Crores |
| Face Value per share | Rs. 10 |
| Price Band | Rs. 137-145 |
| Employee discount | Rs. 0 per share |
| Retail Lot Size | 1000 Shares |
| Listing will at | NSE SME |
How shares are being offered
| Investor Category | Shares Offered |
| Market Maker Shares Offered | 2,70,000 (5.63%) |
| QIB Shares Offered | 22,56,000 (47.07%) |
| NII (HNI) Shares Offered | 6,81,000 (14.21%) |
| Retail Shares Offered | 15,86,000 (33.09%) |
| Total Shares Offered | 47,93,000 (100.00%) |
| Application | Lots | Shares | Amount |
| Individual investors (Retail) (Min) | 2 | 2,000 | ₹2,90,000 |
| Individual investors (Retail) (Max) | 2 | 2,000 | ₹2,90,000 |
| S-HNI (Min) | 3 | 3,000 | ₹4,35,000 |
| S-HNI (Max) | 6 | 6,000 | ₹8,70,000 |
| B-HNI (Min) | 7 | 7,000 | ₹10,15,000 |
Who are the Promoters of Anondita Medicare IPO?
The promoters hold 83.95% of the pre-IPO capital
What are the Objects of Anondita Medicate IPO?
The Company proposes to utilize the Net Proceeds from Issue towards funding the following objects
+Funding capital expenditure requirements for the purchase of equipment/machineries Rs. 6.00 Crore
+ Funding the Working Capital requirement Rs. 35.00 Crore
+General Corporate purposes
Anondita Medicare IPO Lead Managers
Narnolia Financial Services ltd
| Registered Office of the Company |
| Anondita Medicare Ltd. Flat No.704 Narmada Block, N6, Sec-D, Pkt-6 Vasant Kunj, New Delhi, New Delhi, 110070 |
| Who is the Registrar to the IPO? Maashitla Securities Pvt ltd |
Anondita Medicare Financials Snapshot
| Period Ended | 31-Mar-25 | 31-Mar-24 | 31-Mar-23 |
| Assets | 78.27 | 42.92 | 37.8 |
| Total Income | 77.13 | 46.56 | 36.14 |
| Profit After Tax | 16.42 | 3.84 | 0.35 |
| EBITDA | 25.65 | 9.09 | 3.58 |
| Net Worth | 37.87 | 10.59 | 8.69 |
| Reserves and Surplus | 24.58 | 10.39 | 6.55 |
| Total Borrowing | 27.39 | 24.01 | 22.66 |
| Amount in Crore | |||
Performance Indicators
| KPI | Values |
| ROE | 41.71% |
| ROCE | 37.42% |
| Debt/Equity | 0.7 |
| RoNW | 41.71% |
| PAT Margin | 21.32% |
| EBITDA Margin | 33.32% |
| Price to Book Value | 15.07 |
| EPS | 9.08 |
| PER | 15.98 |
How Anondita Medicare IPO compares with the Peers?
| Company Name | P/E (x) | RoNW (%) |
| Anondita Medicare Limited | 38.1 | |
| Cupid Ltd. | 110.38 | 11.96 |
# This is only coverage of News related to Grey Market Premium & subject to rates. We do not deal in grey market premium. We do not recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.
Anondita Medicare IPO Review
by Paresh Gordhandas, CA & Research Analyst
Anondita Medicare Limited, known for its flagship condom brand “COBRA,” has established itself in a sensitive yet fast-growing healthcare segment. The company’s focus on flavored male condoms, strong export base across Southeast Asia, Africa, and the Middle East, and tie-ups with NGOs and government health programs give it a steady demand visibility.
Financially, the company has shown a sharp turnaround. Total income has grown from Rs.36.14 crore in FY23 to Rs.77.13 crore in FY25, while profit after tax jumped significantly from just Rs.0.35 crore in FY23 to Rs.16.42 crore in FY25. EBITDA margins have expanded strongly, reflecting operational efficiency. Net worth has more than tripled over the last two years.
On the flip side, the company still carries borrowings of Rs.27.39 crore, though the rising profitability may ease debt concerns. The business is highly dependent on institutional contracts and global health programs, which adds both stability and concentration risk.
Chanakya’s View: The company operates in a niche healthcare category with strong export orientation and remarkable financial improvement. Given its robust topline growth, margin expansion, and association with reputed agencies, the IPO appears attractive from a medium to long-term perspective. Listing gains cannot be ruled out, considering the sharp rise in profits and improving fundamentals.
Anondita Medicare Limited manufactures flavored male condoms under its flagship brand “COBRA” and has a strong presence in domestic as well as international markets across Southeast Asia, Africa, and the Middle East.
The IPO opens on August 22, 2025 and closes on August 26, 2025. The shares are expected to list on September 1, 2025 on NSE SME.
Q4. How is the financial performance of Anondita Medicare?
The company’s revenue increased from ₹36.14 crore in FY23 to ₹77.13 crore in FY25, while net profit jumped from ₹0.35 crore in FY23 to ₹16.42 crore in FY25. This reflects strong business growth and improving margins.
Given its strong financial turnaround, global presence, and association with NGOs and government programs, the IPO looks promising for medium to long-term investors.
Quicklinks
